NCT02894021

Brief Summary

Lymphoceles, or seromas, are the most frequent complication following mastectomy and are associated or not with axillary dissection occurring in 10 to 90% of cases. It is defined as the presence of a palpable post operative serous accumulation that is bothersome for the patient and requires a puncture and drainage or even several repeated punctures. The presence of seromas is therefore associated with discomfort and pain. Seromas could also be responsible for increased morbidity due to complications such as infection, suture separating, lymphedema, prolonged of hospital stay, or a delay in initiation of adjunct treatment (e.g. chemotherapy, radiotherapy). Some risk factors have been identified, such as obesity, increased post operative drainage of J1 to J3, and arterial hypertension. Different measures have demonstrated the benefits of limiting axillary lymphoceles after dissection : placement of a drain, padding and delay in shoulder mobility. Studies have shown that axillary padding decreases lymphocele development and shortens the length of hospital stay. Some studies based on padding of the mastectomy site also have shown a decrease in post operative seromas; however no study has been done on the usefulness of padding in the mastectomy site alone because they include both padding and a drain or padding of the axillary area. The padding technique the investigators employ is performed at the donor site in breast reconstruction by latissimus dorsi muscle flap, demonstrating a reduction in the rate of seromas. In this study, the classic technique will be compared to padding in the mastectomy site with short drainage (48h).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
3.4 years until next milestone

First Submitted

Initial submission to the registry

September 5, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 9, 2016

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
Last Updated

September 9, 2016

Status Verified

September 1, 2016

Enrollment Period

4.3 years

First QC Date

September 5, 2016

Last Update Submit

September 5, 2016

Conditions

Keywords

paddinglymphocelesprevention

Outcome Measures

Primary Outcomes (1)

  • postoperative lymphoceles

    presence or absence of postoperative lymphoceles

    Day 15

Study Arms (2)

classic closure

ACTIVE COMPARATOR

mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration

Procedure: classic closure

padding

EXPERIMENTAL

areas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.

Procedure: padding

Interventions

mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration

classic closure
paddingPROCEDURE

areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h

padding

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years
  • Female gender
  • Patients with infiltrating or in situ breast cancer
  • Indication of surgical treatment by mastectomy
  • Patient providing written informed consent
  • Patient with health insurance coverage
  • Ability to provide voluntary written informed consent

You may not qualify if:

  • Informed consent cannot be obtain
  • Pregnant or lactating women
  • Patients undergoing immediate breast reconstruction
  • Patients with cancer untreatable by mastectomy, non curative mastectomy: partial mastectomies, preventive mastectomies (BRCA genetic mutations)
  • Patients under legal protection or unable to come to a center
  • Patients unable to express voluntary consent
  • Patients receiving post operative anticoagulants or platelet antiaggregants
  • Patients requiring postoperative anticoagulants
  • Bilateral mastectomy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

CHU Amiens

Amiens, 80054, France

RECRUITING

CH Compiègne

Compiègne, 60321, France

RECRUITING

CH Soissons

Soissons, 02209, France

RECRUITING

MeSH Terms

Conditions

Lymphocele

Condition Hierarchy (Ancestors)

CystsNeoplasmsLymphatic DiseasesHemic and Lymphatic Diseases

Central Study Contacts

Mohamed AIT AMER MEZIANE, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 5, 2016

First Posted

September 9, 2016

Study Start

May 1, 2013

Primary Completion

August 1, 2017

Study Completion

August 1, 2017

Last Updated

September 9, 2016

Record last verified: 2016-09

Locations